Metrion Biosciences Ltd, is a specialist ion channel contract research and drug discovery company, announced today that it has completed a fully subscribed funding round on 14 March. Metrion will use the funds to support the broadening of its ion channel screening capabilities, and continued research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.

Metrion is both revenue generating and is developing a therapeutic drug for auto-immune conditions, supported by a UK government grant. The revenues that are generated are supportive to both providing sustainability to the company (which also keeps them at the forefront of the ion channel biology area, and if they achieve the scientific goals for the auto-immune drug asset then this will open several avenues for fast-growth. The company is based in Granta Park, Cambridge. Sunil Shah (o2h) is a Board Observer and has retained rights to join as a Non-Executive Director.